REDWOOD CITY, Calif.–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on October 30, 2026. One individual was hired by Adicet in October 2026 and granted new hire non-qualified stock options to purchase 1,500 shares of Adicet’s common stock with an exerc